Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus - Report - MDSpire

Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus

  • By

  • Borja del Carmelo Gracia Tello

  • José Miguel García-Bruñén

  • Luis Corredor

  • Natalia Allue Fantova

  • Eva Ma Calvo Beguería

  • Rubén García-Muñío

  • Laura Pérez Abad

  • Jimena Aramburu Llorente

  • Beatriz Martinez Muriel

  • Paula Vidales Miguélez

  • Roxanna Alexandra Morante Mendoza

  • Julia Martínez Artigot

  • Noelia Chicano Nieto

  • Jorge Álvarez Troncoso

  • Luis Martinez-Lostao

  • Adela Marín Ballvé

  • May 8, 2026

  • 0 min

Share

Clinical Report: Increased Levels of Interleukin-6 as Indicators of Short-Term Flares in Systemic Lupus Erythematosus

Overview

This study identifies increased serum levels of interleukin-6 (IL-6) as significant predictors of short-term flares in systemic lupus erythematosus (SLE). Elevated IL-6 levels correlate with a reduced time to subsequent disease flares and may enhance existing biomarkers for disease monitoring.

Background

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by unpredictable flares that can lead to significant organ damage. Identifying reliable biomarkers for predicting disease exacerbations is crucial for timely intervention and improved patient outcomes. Interleukin-6 (IL-6) has been implicated in SLE pathogenesis, yet its role as a predictive marker for imminent flares remains to be fully established.

Data Highlights

FindingValue
Patients with IL-6 > 5 pg/mL48%
Median interval to flare (SLEDAI-2K > 4)10 months shorter

Key Findings

  • 48% of SLE patients had IL-6 levels exceeding 5 pg/mL.
  • Higher IL-6 levels correlated with a significantly shorter duration until the next flare.
  • Increased IL-6 predicted the occurrence of arthritis, nephritis, serositis, and hematologic symptoms.
  • IL-6 demonstrated superior discriminative capability compared to anti-dsDNA, C3, and C4.
  • IL-6 levels may enhance the predictive accuracy of existing biomarkers in SLE management.

Clinical Implications

Clinicians should consider monitoring IL-6 levels in SLE patients as a potential tool for predicting imminent disease flares. This could facilitate timely interventions and improve management strategies to minimize organ damage. However, further validation in broader clinical settings is necessary before routine implementation.

Conclusion

Elevated IL-6 levels are associated with short-term disease reactivation in SLE, suggesting their potential utility in enhancing existing biomarkers for disease monitoring. Continued research is needed to establish IL-6 as a standard predictive marker in clinical practice.

Related Resources & Content

  1. Urowitz et al., Clinical Rheumatology, 2025 -- The Role of Serum APRIL, BAFF, and IL-10 Levels in Assessing Disease Activity and Flare Prediction in Systemic Lupus Erythematosus Is Limited
  2. Clinical Rheumatology, 2023 -- Elevated Levels of Neutralizing Anti-IFN-γ IgG Found in Systemic Lupus Erythematosus Patients Linked to Increased Infection Risk
  3. Clinical Rheumatology, 2022 -- Impact of SARS-CoV-2 on Systemic Lupus Erythematosus: Exploring Endothelial Dysfunction, Atherosclerosis, and Thrombotic Events
  4. New Lupus SLE Clinical Practice Guideline Released | ACR Convergence 2025 | American College of Rheumatology
  5. Clinical Rheumatology — The Relationship Between Dyslipidemia, Inflammation, and Organ Involvement in Systemic Lupus Erythematosus
  6. New Lupus SLE Clinical Practice Guideline Released | ACR Convergence 2025 | American College of Rheumatology
  7. Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: a meta-analysis
  8. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial - ScienceDirect

Original Source(s)

Related Content